Hematology NewsPD-1 checkpoint inhibitors show mettle against relapsed Hodgkin’s lymphomaDecember 7, 2014Transfusion MedicineAggressive LymphomasHodgkin Lymphoma
Hematology TimesSpeaker advocates chemo-based salvage in HLNovember 5, 2014Lymphoma & Plasma Cell DisordersHodgkin Lymphoma
Hematology TimesBrentuximab tops chemo in HL, doc saysNovember 5, 2014Lymphoma & Plasma Cell DisordersHodgkin Lymphoma
Hematology TimesRisk factors for premature menopause in HL survivorsAugust 25, 2014Lymphoma & Plasma Cell DisordersHodgkin Lymphoma
Hematology NewsRepeat biopsy and long-term surveillance key for rare Hodgkin’s lymphoma subtype June 20, 2014Aggressive LymphomasHodgkin Lymphoma
Hematology TimesScreening catches breast cancer early in HL survivorsJune 5, 2014Lymphoma & Plasma Cell DisordersHodgkin Lymphoma
Hematology TimesInhibitor gets breakthrough designation for HLMay 21, 2014Lymphoma & Plasma Cell DisordersPharmacyHodgkin Lymphoma
Hematology TimesOmitting RT can increase risk of relapse in HLMarch 21, 2014Lymphoma & Plasma Cell DisordersHodgkin Lymphoma
Hematology TimesMutations appear to drive lymphoma developmentMarch 13, 2014Lymphoma & Plasma Cell DisordersHodgkin Lymphoma
Hematology TimesBrentuximab vedotin approved in JapanJanuary 22, 2014Lymphoma & Plasma Cell DisordersPharmacyHodgkin Lymphoma
Oncology PracticeVIDEO: Idelalisib shows promise in refractory non-Hodgkin lymphomaDecember 10, 2013Lymphoma & Plasma Cell DisordersAggressive LymphomasHodgkin Lymphoma
Hematology NewsNo survival benefit for routine surveillance scans in classical Hodgkin diseaseJuly 8, 2013Translational ResearchTransfusion MedicineIndolent LymphomaHodgkin Lymphoma
Hematology TimesPanobinostat shows promise in refractory Hodgkin lymphomaDecember 9, 2009Lymphoma & Plasma Cell DisordersHodgkin Lymphoma
